investors.bio-techne.com Open in urlscan Pro
143.204.215.34  Public Scan

Form analysis
1 forms found in the DOM

POST

<form id="fileUploadForm" enctype="multipart/form-data" method="post" target="fileUploadIframe"><input type="file" id="fileSelector" name="file" style="display: none;"><input name="filename" type="hidden"></form>

Text Content

800 343 7475ir@bio-techne.com bio-techne.com


 * Overview
 * News / Events
 * Company Information
 * Strategy
 * Financial Information
 * Stock Data
 * SEC Filings
 * Corporate Governance


Navigation


   INVESTOR RELATIONS

 * Overview
 * News / Events
   * Overview
   * Press Releases
   * IR Calendar
   * Email Alerts
 * Company Info
   * Overview
   * Profile
   * Presentations
   * Management Team
   * Contacts
   * FAQ
 * Financial Info
   * Overview
   * Balance Sheet
   * Income Statement
   * Cash Flow
   * Financial Results
   * Annual Reports
 * Stock Data
   * Overview
   * Quote
   * Charts
   * Historical Data
 * SEC Filings
   * Overview
   * All SEC Filings
   * 10-K Filings
   * Quarterly Reports
   * Section 16 Filings
 * Governance
   * Overview
   * Board of Directors
   * Board Committees
   * Governance Documents




BIO-TECHNE INVESTORS WEBSITE

WHERE SCIENCE INTERSECTS INNOVATION™

As Bio-Techne, we have united multiple brands to provide a unique and
comprehensive product portfolio. Together, our brands provide world class
products and services for life-science research and clinical applications.


LATEST NEWS

Oct 6, 2022


BIO-TECHNE COMMERCIALIZES AUTOMATED MULTI-OMIC RNASCOPE ASSAYS FOR SPATIAL
VISUALIZATION OF RNA AND PROTEIN BIOMARKERS IN FFPE TISSUES

View All Get Alerts


UPCOMING EVENTS

Oct 27, 2022 • 8:00am CDT


ANNUAL MEETING OF SHAREHOLDERS

View All


LATEST PRESENTATION

April 7, 2022


CORPORATE PRESENTATION – MARCH 2022

View Presentation View All


LATEST QUARTERLY RESULTS


FY 2022

Fiscal Year Ended Jun 30, 2022

PDF HTML
Earnings Release
Audio
Earnings Webcast
PDF
Annual Report
PDF HTML
10-K Filing
ZIP XLS HTML
XBRL
Get Alerts


73.2%

Adjusted Gross Margin of 73.2%


$2.05

Adjusted EPS of $2.05


$288.2

Revenue of $288.2 million


SIGN UP FOR E-MAIL ALERTS

Sign up today

For the Fiscal Year ended Jun 30, 2022

View Annual Report Get Alerts


STOCK INFORMATION


BIO-TECHNE CORPORATION

NASDAQ: TECH

Oct 06, 2022 • 4:00 PM EDT  |  View Detailed Stock Info

Price $309.08

Change 0.53 (0.17%)

Volume 229.15k

Day Range
52 Week Range
Day Range
281.42306.33

311.56531.80
52 Week Range


COMPANY OVERVIEW



Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of
high-quality purified proteins and reagent solutions - notably cytokines and
growth factors, antibodies, immunoassays, biologically active small molecule
compounds, tissue culture reagents, and cell and gene therapy workflow solutions
including T-Cell activation technologies. Bio-Techne’s portfolio also includes
protein analysis solutions, sold under the ProteinSimple brand name, that offer
researchers efficient and streamlined options for automated Western blot and
multiplexed ELISA workflow. These reagent and protein analysis solutions are
sold to biomedical researchers, as well as clinical research laboratories, and
constitute the Protein Sciences Segment.

Bio-Techne also develops and manufactures diagnostic products including
FDA-regulated controls, calibrators, blood gas and clinical chemistry controls,
and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools
include advanced tissue-based in situ hybridization assays (ISH) for research
and clinical use, sold under the ACD brand, as well as a portfolio of clinical
molecular diagnostic oncology assays including the ExoDx® Prostate test
(EPI) for prostate cancer diagnosis. These diagnostic and genomic products
comprise Bio-Techne’s Diagnostics and Genomics Segment.

Bio-Techne products are integral components of scientific investigations into
biological processes and molecular diagnostics, revealing the nature, diagnosis,
etiology and progression of specific diseases. They aid in drug discovery
efforts and provide the means for accurate clinical tests and diagnoses. With
thousands of products in its portfolio, Bio-Techne generated approximately $1.1
Billion in net sales in fiscal 2022 and has approximately 3,000 employees
worldwide.




FAST FACTS



Net Sales (July 2021 to June 2022)


$1.1 BILLION

Employees Worldwide


~3,000

Products


500,000+

Journal citations


350,000+

Incorporated in Minneapolis, Minnesota


1981




LEADERSHIP

Our people are our backbone. Touting years of experience in a variety of fields,
our leadership team is a source of our success.

View Management Team View Board of Directors


IR CONTACT INFORMATION


COMPANY INFORMATION

Corporate Secretary
614 McKinley Place NE
Minneapolis, MN 55413


INVESTOR RELATIONS

David Clair
T: 612-656-4416
ir@bio-techne.com



TRANSFER AGENT

American Stock Transfer
6201 15th Avenue
Brooklyn, NY 11219
T: 800-937-5449
help@astfinancial.com


 * Email Alerts
 * Contacts
 * RSS News Feed

614 McKinley Place NE
Minneapolis, MN 55413
USA

TEL 612 379 2956
Toll-free 800 343 7475
FAX 612 656 4400

WHO WE ARE

 * About Bio-Techne
 * Bio-Techne Brands
 * Careers
 * Corporate & Social Responsibility
 * Terms and Conditions

INVESTOR RELATIONS

 * Overview
 * News / Events
 * Company Information
 * Financial Information
 * Stock Data
 * SEC Filings
 * Corporate Governance

STAY CONNECTED

 * 
 * Contact Us

UTILITY FOOTER MENU

 * Privacy and Cookie Policy
 * Site Map
 * © Copyright 2022 Bio-Techne. All Rights Reserved.



Live chat:Chat now